- Sector: Healthcare > Industry: Diagnostic & Testing Substances
- Founded: 2003
- Headquarters: Seattle, WA
- nanostring.com
NanoString Technologies sees Q3 revs below consensus
- Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $25.9-26.9 mln vs. $27.68 mln Capital IQ Consensus Estimate. Guidance is including product and service revenue of ~$16.9 mln and collaboration revenue of $9.0 mln to $10.0 mln. This unaudited estimate, based on management's preliminary financial analysis, is lower than the company's previous guidance for product and service revenue of $19.5 mln to $21.5 mln for the third quarter of 2017.
- "While we are disappointed that softness in our instrument and consumable sales drove a shortfall in our product and service revenue in the third quarter, we believe that initiatives underway will strengthen the value proposition of our products and enhance the growth of the business over time."
Description
NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company's nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -13.17% | -54.45% |
| Operating margin | -9.58% | -47.61% |
| EBITD margin | - | -44.26% |
| Return on average assets | -14.08% | -42.96% |
| Return on average equity | -74.62% | -289.60% |
| Employees | 407 |
No comments:
Post a Comment